Casodex/Zoladex Biomarkers in Localised Prostate Cancer

Tampere University

Status and phase: Completed; Phase 4

Conditions: Prostate Cancer

Treatments: Drug: bicalutamide (Casodex), goserelin (Zoladex)

Study type: Interventional

Funder types: Other

Identifiers

NCT00293696

D6876C00001

Details and patient eligibility

About

To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones

Enrollment: 30 patients

Sex: Male

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Histologically confirmed localised prostate biopsy specimen that contains sufficient tumour for evaluation of cell proliferation and apoptosis markers
2. Patients who are scheduled for radical prostatectomy with curative intents

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)